Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Marek Šoltys"'
Publikováno v:
Molecular Systems Design & Engineering. 6:368-380
Liposomal formulations can be advantageous in many scenarios such as targeted delivery to reduce the systemic toxicity of highly potent active pharmaceutical ingredients (APIs), to increase drug bioavailability by prolonging systemic circulation, to
Publikováno v:
International Journal of Pharmaceutics. 555:19-27
Increasing the dissolution rate of poorly water-soluble active pharmaceutical ingredients (APIs) is a key strategy used for improving their oral bioavailability. One of the formulation approaches is API loading to mesoporous carrier particles, which
Autor:
Miloslav Lhotka, Jakub Mužík, Ondřej Kašpar, David Zůza, František Štěpánek, Marek Šoltys, Denisa Lizoňová, Pavel Ulbrich
Publikováno v:
Microporous and Mesoporous Materials. 274:61-69
Silica particles with a unique multi-level pore structure have been prepared in order to enable efficient melt-in amorphisation of pharmaceutical substances. The dissolution rate of drugs with a low aqueous solubility can be enhanced by their convers
Autor:
Nataša Škalko-Basnet, David Zůza, Tereza Boleslavská, Marek Šoltys, Josef Beranek, Gøril Eide Flaten, Pavel Kovačík, František Štěpánek, Martin Balouch, Sarah Machač Akhlasová
The sorption of poorly aqueous soluble active pharmaceutical ingredients (API) to mesoporous silica carriers is an increasingly common formulation strategy for dissolution rate enhancement for this challenging group of substances. However, the succes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45026ee30185068611ba67fbaf477917
https://hdl.handle.net/10037/24631
https://hdl.handle.net/10037/24631
Liposomal formulations can be advantageous in a number of scenarios such as targeted delivery to reduce the systemic toxicity of highly potent Active Pharmaceutical Ingredients (APIs), to increase drug bioavailability by prolonging systemic circulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0f9948e223e7666dcced4e8bc603e57
https://doi.org/10.1101/2020.05.11.087742
https://doi.org/10.1101/2020.05.11.087742
Autor:
Marek Šoltys, Sergei G. Kazarian, Jakub Mužík, František Štěpánek, Josef Beranek, Denisa Lizoňová
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 130:327-335
Drug amorphisation by loading to inorganic mesoporous carriers represents an emerging area of improving the dissolution rate and bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs). In this work, for the first time, a mol
Autor:
Petr Sysel, Marek Lanč, Pavel Ulbrich, Karel Friess, Ondřej Vopička, František Štěpánek, Kristián Fónod, Martina Klepić, Marek Šoltys, Miloslav Lhotka
Publikováno v:
Polymer. 144:33-42
We report on synthesis, preparation and characterization of newly prepared hyperbranched polyimide (HBPI) based on 4,4´-(hexafluoroisopropylidene)diphthalic anhydride (6FDA) and 4,4′,´´-triaminotriphenylmethane (TTM). HBPI material was synthesiz
Autor:
Miloslav Lhotka, Marek Šoltys, František Štĕpánek, Martin Balouch, Pavel Ulbrich, Aleš Zadražil, Ondřej Kašpar, Pavel Kovačík
Publikováno v:
Chemical Engineering Journal. 334:1135-1147
Despite the wide application interest in mesoporous silica micro- and nano-particles and a number of synthesis routes reported in the literature, the question of chemical engineering scale-up of the synthetic routes has rarely been addressed. The pre
Publikováno v:
Colloids and Surfaces A: Physicochemical and Engineering Aspects. 628:127358
Silica particles find applications in drug delivery and bio-sensing, where their large specific surface area can accumulate or release biologically active substances. Such applications would benefit from the ability to control diffusion access to the
Publikováno v:
AAPS PharmSciTech. 20
The manufacture of personalised medicines where specific combinations of active pharmaceutical ingredients (APIs) and their dose within a tablet would be adjusted to the needs of individual patients, would require new manufacturing approaches compare